Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Sermorelin has had a strange career. Approved by the FDA in 1997 as a pediatric growth-hormone drug [1], pulled from the commercial market in 2009 by its own manufacturer, then quietly reborn through compounding pharmacies as the anti-aging clinic's favorite injectable. The drug never failed a safety review. Nobody flagged it as ineffective. It just stopped being commercially worth making.
That history matters, because most of what's written about the sermorelin peptide online either treats it as a longevity panacea or dismisses it as a regulatory orphan. The honest read of the data sits somewhere awkward in the middle.
Sermorelin is a 29-amino-acid fragment of growth hormone-releasing hormone [2], the molecule the hypothalamus uses to tell the pituitary to release growth hormone. Specifically, it's the first 29 residues of native GHRH, which turn out to be the biologically active portion. The rest is structural.
That makes it what pharmacologists call a growth hormone secretagogue. It doesn't add growth hormone to the body. It asks the pituitary to make more of its own.
The mechanism: sermorelin binds GHRH receptors on somatotroph cells in the anterior pituitary, which then synthesize and release GH in pulses. The hypothalamus still produces somatostatin, the brake on GH release, so the feedback loop stays intact. If GH or IGF-1 climb too high, somatostatin shuts the pulse down. The body keeps its safety mechanisms.
Half-life is short, under 15 minutes in plasma [3], which is why dosing is timed to align with the body's natural GH pulse during slow-wave sleep. Inject before bed, and the drug works during the window the pituitary is already primed to fire.
This is the distinction that explains everything else about how the drug is positioned and prescribed.
Recombinant human growth hormone, the rhGH in brand-name products like Genotropin, Norditropin, and Humatrope, is the finished hormone itself. You inject it, it circulates, it binds GH receptors throughout the body, and it bypasses the hypothalamic-pituitary axis entirely. The pituitary, sensing high circulating GH, shuts down. Over time, that suppression can become functional atrophy of endogenous production.
Sermorelin works upstream. The pituitary still does the work, the hypothalamus still regulates the pulse, and IGF-1 rises gradually rather than getting force-fed into the system. Proponents argue this is more physiologic: a hormonal profile closer to what a healthy 25-year-old produces naturally, rather than the flat plateau of exogenous GH.
The catch: sermorelin can only do as much as the pituitary is capable of. If somatotroph function is genuinely impaired by pituitary damage, tumor, or surgical resection, sermorelin won't rescue you. RhGH will. The drugs are not interchangeable. They're for different problems wearing similar costumes.
Sermorelin acetate, sold as Geref by EMD Serono, got FDA approval in 1997 for diagnosing and treating idiopathic growth hormone deficiency in children [4][5]. Separate NDAs covered the diagnostic and treatment indications.
In 2008, EMD Serono told the FDA it was discontinuing Geref, first the 0.05 mg formulation, then the 0.5 mg and 1.0 mg vials later that year. The company asked for both NDAs to be withdrawn. The FDA published the formal withdrawal in May 2009, effective the following month [6].
Here's the part that gets misreported constantly. In March 2013, the FDA published a determination (Federal Register 2013-04827) stating explicitly that Geref was not withdrawn from sale for reasons of safety or effectiveness [7]. It was a business decision. The pediatric GHD market was small, rhGH had captured it, and Geref wasn't worth manufacturing anymore.
That 2013 determination is what makes everything that followed possible. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare drugs that have been discontinued for commercial reasons, but not drugs withdrawn for safety [8]. The FDA's own ruling kept the door open.
So the current status, as of 2026: no FDA-approved commercial sermorelin product exists. It's listed in the Orange Book's Discontinued Drug Product List. Licensed compounding pharmacies prepare it under 503A with a valid prescription. It's not on the FDA's Category 2 Bulk Drug Substances List, and it never was — a different regulatory bucket than CJC-1295 and ipamorelin, which the FDA placed in Category 2 in 2023 and then removed in 2024 to evaluate through PCAC, leaving them in a gray zone rather than settled [9].
Worth flagging: 503A compounding rules have shifted aggressively in the GLP-1 category over the past eighteen months, and the regulatory framework for compounded peptides may not stay stable. The category is dynamic.
Three populations show up in the clinical literature and the prescribing patterns.
Adults with documented age-related GHD. GH production declines steadily with each passing decade after age 30. Some adults end up with IGF-1 levels well below the age-adjusted normal range, with symptoms that map to GH deficiency: poor sleep architecture, central adiposity that won't respond to diet, slow recovery from exercise, and reduced lean mass. These patients are the closest analog to a legitimate medical indication, though the diagnosis requires endocrine workup, not a quiz on a telehealth site.
Adults using sermorelin off-label for body composition, recovery, or general anti-aging. This is the bulk of current prescribing. Wellness clinics, longevity practices, men's health clinics. The clinical rationale is real, since IGF-1 does decline with age and GH pulsatility does flatten, but the evidence is thin that sermorelin meaningfully reverses age-related changes in otherwise healthy adults. We'll get to that.
Pediatric GHD patients. Historically the FDA-approved use. In practice, rhGH dominates this space now and pediatric sermorelin prescribing is rare.
Sermorelin is not appropriate for anyone with active or recent malignancy (IGF-1 has proliferative signaling effects), pregnant or breastfeeding patients, untreated hypothyroidism (which blunts the GH response anyway), or patients with real hepatic or renal disease. Competitive athletes should know it's on WADA's prohibited list [10].
Here's where the honest version diverges from the marketing version.
The pediatric GHD evidence is solid enough that it supported FDA approval in 1997. The adult evidence is a different story: small trials, short durations, mostly biomarker endpoints rather than clinical outcomes.
The two studies most often cited are worth looking at directly. Corpas and colleagues gave sermorelin to 9 young men and 10 elderly men for 14 days at two doses, with a washout between [11]. The high-dose arm raised mean 24-hour GH, peak GH amplitude, and IGF-1 in the elderly group toward levels seen in the young controls. Khorram and colleagues ran a 16-week single-blind, placebo-controlled trial in older adults, administering nightly doses of a GHRH analog, and reported real increases in GH release in the 2-hour post-injection window, plus higher 12-hour mean GH at both 4 and 16 weeks.
Nineteen participants. Sixteen weeks.
That's the largest adult RCT in the literature. There's no Phase 3 trial of sermorelin in adults. There's no long-term outcome data on body composition, fracture risk, cardiovascular events, or mortality. What exists is biomarker improvement in small samples over short periods, plus expert reviews from Walker 2006 and Sigalos and Pastuszak 2018 [12] [13] that synthesize that evidence into a generally favorable but cautious assessment.
To be clear: this isn't evidence of absence. Sermorelin's mechanism is sound, the biomarker responses are consistent, and the safety profile from the original pediatric approval is reassuring. It's a drug that probably does what its proponents say it does in the patients they describe. We just don't have the trial data to confirm it the way we'd want to.
Patients and clinicians who use sermorelin describe a fairly consistent arc.
The first thing most people notice is sleep. Within one to three weeks: deeper sleep, more vivid dreams, easier time falling asleep. This tracks with the mechanism. Endogenous GH releases during slow-wave sleep, and sermorelin amplifies that pulse.
Body composition changes show up later. Three to six months in, patients report modest reductions in visceral fat and small gains in lean mass, particularly when sermorelin is combined with resistance training. The published Khorram data on body composition in the 16-week arm is consistent with this, though the sample is too small to draw firm conclusions about magnitude.
Recovery from exercise, skin quality, and energy levels are the soft endpoints that show up in patient self-report but aren't well captured in the formal literature.
What sermorelin doesn't do, regardless of what some clinic websites suggest: it doesn't reverse aging, it doesn't match the body composition effects of rhGH or testosterone replacement, and it doesn't produce dramatic transformation in patients with normal baseline IGF-1. The patients who report the most benefit tend to be those starting from a deficit.
The original FDA clinical trial population of 350 patients is the cleanest dataset we have [14]. The dominant adverse event was injection site reaction (pain, swelling, or redness at the injection point), affecting a notable minority of patients, with very few discontinuing therapy because of it. Everything else came in at under 1% in trials: headache, flushing, occasional dizziness, dysgeusia (a strange or metallic taste), and mild somnolence.
Post-marketing and clinical practice have added a few items to the list: water retention and peripheral edema (a GH-mediated effect on fluid balance), joint stiffness, occasional paresthesia, and sleep disturbances in some patients. Sometimes the same vivid-dream effect that other patients describe as a benefit.
The FDA Adverse Event Reporting System (FAERS) includes reports of chronic kidney disease and drug-ineffective outcomes associated with sermorelin. Worth reading carefully: FAERS captures associations, not causation. The CKD signal almost certainly reflects the comorbidity profile of patients who pursue GH-axis therapy (metabolic syndrome, hypertension, and the conditions that drive both renal disease and the desire for hormonal optimization) rather than a direct drug effect. Formal pharmacovigilance work would be needed to separate signal from confounding.
The one item that warrants ongoing monitoring is IGF-1. Chronically elevated IGF-1 has been associated in epidemiological literature with increased risk for certain cancers. This risk has not been quantified for sermorelin specifically, and most patients on standard protocols don't reach the elevations that would concern an endocrinologist. But it's the reason IGF-1 labs every 6 to 12 weeks are standard, and the reason patients with cancer history shouldn't be on it.
The safety case for sermorelin over rhGH rests on the preserved feedback loop. Because somatostatin can still shut the pulse down, sermorelin patients are theoretically protected from the GH-excess problems (acromegalic features, severe insulin resistance) that have shown up in rhGH abuse cases. The trouble is we don't have head-to-head long-term safety data to confirm this, but the mechanism makes it plausible.
Four peptides come up in this conversation, and they don't do the same thing.
Sermorelin is GHRH 1-29, half-life under 15 minutes, acts on GHRH receptors, preserves feedback. The original.
CJC-1295 is a modified GHRH analog with a much longer half-life, days in the DAC (drug affinity complex) version, designed to produce sustained GHRH receptor activation rather than pulses [15]. Different pharmacokinetic philosophy entirely. Some clinicians argue the loss of pulsatility is a downside; others argue convenience and steadier IGF-1 elevation are worth it. CJC-1295 was placed on the FDA Category 2 list in 2023 and removed by the FDA in 2024 (now a regulatory gray zone); sermorelin was never on it.
Ipamorelin is a different class altogether. It's a GHRP, a ghrelin receptor agonist, not a GHRH analog [16]. It triggers GH release through a separate pathway, with minimal effect on cortisol or prolactin (an issue with older GHRPs like GHRP-6) [17]. Often combined with CJC-1295 to hit both receptor systems simultaneously.
Tesamorelin is the regulatory comparator that matters most. It's a stabilized GHRH analog, FDA-approved in 2010 as Egrifta SV for HIV-associated lipodystrophy, and it's the only currently-approved GHRH-class drug on the U.S. market [18] [19]. Tesamorelin shows meaningful visceral fat reduction in its approval trials. It's expensive and narrowly indicated, and not used in general anti-aging practice, but it's the proof of concept that GHRH analogs can clear FDA review when a sponsor decides to do the trials.
In practice, many compounded protocols stack a GHRH analog (sermorelin, CJC-1295) with a GHRP (ipamorelin) to amplify the GH pulse. The evidence for combination therapy in adults is even thinner than the evidence for sermorelin alone, but it's the default in most longevity practices.
Sermorelin is a real drug with a real mechanism and a strange regulatory life. The biology is well-understood. The pediatric efficacy data is solid. The adult efficacy data is genuinely thin (small trials, short durations, biomarker endpoints), and anyone claiming otherwise is selling something.
The safety profile from the original approval is reassuring at standard doses. The preserved feedback loop is a meaningful theoretical advantage over rhGH. The injection-site reaction is the most common real-world issue. The IGF-1 monitoring is non-negotiable.
For readers considering sermorelin, the relevant factor is baseline biology. The patients most likely to benefit are adults with documented low IGF-1 and symptoms consistent with GH decline, working with a prescriber who runs labs and adjusts dose accordingly. The patients least likely to benefit are healthy adults with normal IGF-1 hoping for dramatic body composition change.
A few things are worth flagging. The marketing in this category runs well ahead of the data. The regulatory framework for compounded peptides is less stable than it looks. And the quality gap between legitimate clinical practice and direct-to-consumer convenience is wider than most patients realize.
Sermorelin probably does what its mechanism suggests it does. We just wish someone had done the trial to prove it.
There's no FDA-approved commercial product today. Geref was approved in 1997 for pediatric growth-hormone deficiency and discontinued in 2009 for business reasons — the FDA confirmed in 2013 it was not pulled for safety or effectiveness. It's now prepared by licensed 503A compounding pharmacies with a prescription, and it was never on the FDA Category 2 list. (CJC-1295 and ipamorelin were placed in Category 2 in 2023, but the FDA removed them in 2024 to evaluate through PCAC.)
Sermorelin is a growth-hormone secretagogue: it prompts your own pituitary to release GH in natural pulses, with the somatostatin feedback loop intact, rather than injecting finished hormone the way rhGH does. The trade-off is that it can only do as much as your pituitary is capable of — in true pituitary failure, rhGH works and sermorelin won't.
The realistic sermorelin benefits are gradual, not dramatic. Most people notice deeper sleep within one to three weeks. Modest visceral-fat reduction and small lean-mass gains tend to show up around three to six months, especially alongside resistance training. It does not reverse aging or match the body-composition effects of rhGH or testosterone, and the benefit is largest in people starting from a documented deficit.
The most common issue is an injection-site reaction; headache, flushing, dizziness, an odd taste, water retention, and joint stiffness are less common. Because IGF-1 has proliferative signaling, IGF-1 monitoring every 6–12 weeks is standard, and it's not appropriate during active or recent cancer, pregnancy or breastfeeding, or untreated hypothyroidism.
Many longevity protocols pair a GHRH analog (sermorelin or CJC-1295) with a GHRP (ipamorelin) to hit both GH-release pathways at once. The human evidence for combination therapy is even thinner than for sermorelin alone, so it should be treated as off-label and clinician-supervised.
Editorial note: Informational only — not medical advice. Peptide therapy decisions should be made with a licensed healthcare provider familiar with your medical history. See our methodology. Last reviewed June 2026; updated July 16, 2026 to correct the FDA Category 2 status of CJC-1295 and ipamorelin.